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Abstract
Aims: Limited data are currently available on midterm outcomes after implantation of everolimus-eluting 
bioresorbable vascular scaffolds (BVS) for treatment of acute ST-elevation myocardial infarction (STEMI).
Methods and results: Patients presenting with STEMI and undergoing primary percutaneous coronary inter-
vention in the initial experience with BVS were evaluated and compared with patients treated with everolimus-
eluting metal stents (EES) by applying propensity matching. Quantitative coronary angiography analysis, and 
18-month clinical follow-up were reported. A total of 302 patients were analysed, 151 with BVS and 151 with 
EES. Baseline clinical characteristics were similar between groups. Final TIMI 3 flow was 87.4% vs. 86.1%, 
p=0.296. At 18-month follow-up, all-cause mortality was 2.8% vs. 3.0% in the BVS and EES groups respec-
tively, p=0.99; the MACE rate was higher in the BVS group (9.8% vs. 3.6%, p=0.02); target lesion revasculari-
sation was 5.7% vs. 1.3%, p=0.05. The 30-day MACE rate in BVS patients without post-dilatation was 6.8%, 
while in patients with post-dilatation it was 3.6%. Scaffold thrombosis (ST) occurred primarily in the acute phase 
(acute ST 2.1% vs. 0.7%, p=0.29; subacute 0.7% vs. 0.7%, p=0.99; late 0.0% vs. 0.0%; very late 1.5% vs. 0.0%, 
p=0.18). All three BVS cases with acute ST had no post-dilatation at the index procedure.
Conclusions: STEMI patients treated during the early experience with BVS had similar acute angio-
graphic results as compared with the EES group. Clinical midterm follow-up data showed a higher clinical 
events rate compared with metal stents. The majority of clinical events occurred in the early phase after 
implantation and mainly in cases without post-dilatation. Optimisation of the implantation technique in the 
acute clinical setting is of paramount importance for optimal short and mid-term outcomes.
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Midterm outcomes of BVS in STEMI
Introduction
Bioresorbable vascular scaffolds (BVS) have recently been intro-
duced as a novel approach for treatment of coronary artery disease, 
providing transient vascular support and drug delivery, potentially 
restoring the vascular physiology after device bioresorption1-4.
The theoretical advantages of this novel technology, such as late 
lumen enlargement, restoration of coronary vasomotion and plaque 
sealing, make this device appealing for patients with ruptured thin-
capped lipid-rich soft plaques in general5-7 and thrombotic lesions 
in acute coronary syndromes and STEMI in particular8-10. Due to 
vasoconstriction and presence of thrombus, the treatment of acute 
lesions is often associated with device undersizing and the occur-
rence of malapposition after thrombus resolution. Theoretically, 
the complete bioresorption of the device would avoid the pres-
ence of long-term malapposed struts. In addition, the wider struts 
of the BVS could entrap thrombotic material and reduce distal 
embolisation11. Futhermore, polymer bioresorption and concomi-
tant formation of a neointimal layer given by connective tissue 
and smooth muscle cells could stabilise the plaque, creating a neo-
thick fibrous cap, without the long-term permanence of metallic 
material in the vessel wall5.
Initial small cohort studies with short follow-up and rela-
tively selected populations reported encouraging results after 
BVS implantation in acute patients; however, currently only lim-
ited data are available on the midterm performance of this novel 
device in patients presenting with acute myocardial infarction11-13. 
Given this background, we analysed patients presenting with 
ST-elevation myocardial infarction (STEMI) treated with BVS 
and we compared angiographic and 18-month clinical results with 
a matched population implanted with everolimus-eluting stents 
(EES).
Methods
Patients presenting with ST-segment elevation myocardial infarc-
tion and treated with BVS at the Thoraxcenter, Erasmus MC in 
Rotterdam between November 2012 and December 2014 were 
evaluated for the present analysis. Subjects included were patients 
≥18 years old admitted with STEMI. Culprit lesions were located 
in vessels within the upper limit of 3.8 mm and the lower limit of 
2.0 mm by online quantitative coronary angiography (QCA). The 
BVS was implanted according to the manufacturer’s sizing matrix. 
The BVS with a nominal diameter of 2.5 mm was implanted in 
vessels ≥2.0 and ≤3.0 mm by online QCA; the 3.0 mm BVS 
was implanted in vessels ≥2.5 and ≤3.3 mm by online QCA; and 
the 3.5 mm BVS was implanted in vessels ≥3.0 and ≤3.8 mm. 
For each nominal diameter a further expansion of 0.5 mm was 
allowed. All patients were loaded with unfractionated heparin (70-
100 UI/kg for an activated clotting time between 250 and 300 s), 
and dual antiplatelet therapy after treatment was planned to last 
12 months. Exclusion criteria comprised pregnancy, known intol-
erance to contrast medium, uncertain neurological outcome after 
cardiopulmonary resuscitation, previous percutaneous coronary 
intervention (PCI) with the implantation of a metal stent, left main 
STEMI cases treated with BVS
(N=161)
STEMI cases treated with EES
(N=1,145)
BVS cases matched with EES cases
with at least 2 years of follow-up available
BVS
(N=151)
EES
(N=151)
Angiographic and procedural data
(N=151)
Angiographic and procedural data
(N=151)
6 patients declined to participate in follow-up All clinical follow-up available
18-month clinical outcomes
Figure 1. Flow chart of the study.
(LM) disease, previous coronary artery bypass grafting (CABG), 
and participation in another investigational drug or device study 
before reaching the primary endpoints.
Propensity score analysis was applied to match each STEMI 
patient treated with BVS to a comparable patient treated with an 
everolimus-eluting stent (EES) in our institution with an available 
follow-up of at least two years.
Baseline and post-scaffold/stent implantation quantitative coro-
nary angiographic analyses were performed and clinical outcomes 
at the 18-month follow-up were evaluated (Figure 1).
STUDY DEVICE
The second-generation BVS (Absorb BVS; Abbott Vascular, 
Santa Clara, CA, USA) is a balloon-expandable scaffold consist-
ing of a polymer backbone of poly-L-lactide (PLLA) coated with 
a thin layer of a 1:1 mixture of an amorphous matrix of poly- D, 
L-lactide (PDLLA) polymer and 100 μg/cm2 of the antiprolifera-
tive drug everolimus. Two platinum markers located at each BVS 
edge allow enhanced visualisation of the radiolucent BVS during 
angiography or other imaging modalities. The PDLLA controls the 
release of everolimus and 80% of the drug is eluted within the 
first 30 days. Both PLLA and PDLLA are fully bioresorbable. The 
polymers are degraded via hydrolysis of the ester bonds, and the 
resulting lactate and its oligomers are transformed to pyruvate and 
metabolised in the Krebs cycle. Small particles, less than 2 μm in 
diameter, have also been shown to be phagocytised and degraded 
by macrophages. According to preclinical studies14, complete 
bioresorption of the polymer backbone occurs from two to three 
years after implantation15.
CONTROL DEVICE
The everolimus-eluting coronary stent system is a balloon-expand-
able metallic platform stent manufactured from a flexible cobalt 
chromium alloy with a multicellular design and coated with a thin 
non-adhesive, durable, biocompatible acrylic, and fluorinated 
everolimus-releasing copolymer.
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Quantitative coronary angiographic analysis
Angiographic views with minimal foreshortening of the lesion and 
limited overlap with other vessels were used whenever possible for 
all phases of the treatment. Analyses pre- and post-treatment were 
performed in matched angiographic views. In case of a thrombotic 
total occlusion, pre-procedure quantitative coronary angiographic 
analysis was performed as proximally as possible from the occlu-
sion (in case of a side branch distally to the most proximal take-off 
of the side branch), as previously reported11. Intracoronary thrombus 
was angiographically identified and scored in five grades as pre-
viously described16,17. Thrombus grade was assessed before proce-
dure and after thombectomy. The two-dimensional angiograms were 
analysed with the CAAS 5.10 analysis system (Pie Medical BV, 
Maastricht, The Netherlands). In each patient, the treated region and 
the peri-treated regions (defined as 5 mm proximal and distal to the 
device edge) were analysed. The QCA measurements included ref-
erence vessel diameter (RVD), percentage diameter stenosis, mini-
mal lumen diameter (MLD), and maximal lumen diameter (Dmax). 
Acute gain was defined as post-procedural MLD minus pre-proce-
dural MLD (an MLD value equal to zero was applied when the cul-
prit vessel was occluded pre-procedurally).
PROCEDURAL-CLINICAL OUTCOMES AND DEFINITIONS
Device success was defined as successful delivery and deployment 
of the device with the attainment of <30% final residual stenosis. 
Procedure success was defined as device success and no major 
periprocedural complications (emergent CABG, coronary perfora-
tion requiring pericardial drainage, residual dissection impairing 
vessel flow – TIMI flow 2 or less). All deaths were considered 
cardiac unless an undisputed non-cardiac cause was identified. 
Target lesion revascularisation (TLR) was defined as clinically 
driven if at repeat angiography the diameter stenosis was ≥70%, 
or if a diameter stenosis 50% was present in association with (i) 
presence of recurrent angina pectoris, related to the target vessel, 
(ii) objective signs of ischaemia at rest (ECG changes) or during 
exercise test, related to the target vessel, and (iii) abnormal results 
of any functional diagnostic test. Scaffold/stent thrombosis was 
defined according to the Academic Research Consortium defini-
tion18. Major adverse cardiac events (MACE) were defined as the 
composite of cardiac death, any re-infarction (Q- or non-Q-wave), 
emergent bypass surgery (CABG), or clinically driven TLR.
Ethics
This is an observational study, performed according to the privacy 
policy of the Erasmus MC and to the Erasmus MC regulations 
for the appropriate use of data in patient-oriented research, which 
are based on international regulations, including the declaration of 
Helsinki. The BVS received the CE mark for clinical use, indicated 
for improving coronary lumen diameter in patients with ischae-
mic heart disease due to de novo native coronary artery lesions 
with no restriction in terms of clinical presentation. Therefore, the 
BVS can be currently used routinely in Europe in different settings 
comprising STEMI without a specific written informed consent in 
addition to the standard informed consent to the procedure. Given 
this background, a waiver from the hospital Ethical Committee 
was obtained for written informed consent, as according to Dutch 
law written consent is not required, if patients are not subject to 
acts other than as part of their regular treatment.
On the other hand all the follow-up clinical data reported in 
the present study are derived from patients who consented to 
participate in this registry being clinically followed-up. A ques-
tionnaire was sent to all living patients with specific queries on 
rehospitalisation and cardiovascular events. For patients who 
suffered an adverse event at another centre, medical records or 
discharge letters from the other institutions were systematically 
reviewed. General practitioners and referring physicians were 
contacted for additional information if necessary.
STATISTICAL ANALYSIS
A propensity score matching was performed using a proprietary 
macro developed and tested for SPSS version 22.0 (IBM Corp., 
Armonk, NY, USA). First, the programme performed a logistic 
regression to score all patients according to the treatment (BVS vs. 
EES), using as covariates clinical and procedural parameters: age 
(years), sex (male/female), cardiogenic shock (yes/no), hyperten-
sion (yes/no), hypercholesterolaemia (yes/no), smoking (yes/no), 
diabetes mellitus (yes/no), pre-procedure TIMI flow, culprit ves-
sel. Second, the macro searched and selected the best match case 
of the EES group for every BVS case according to the absolute 
value of the difference between the propensity score of BVS and 
EES cases under consideration. Patients in the two groups were 
matched through a greedy algorithm based on local optimisation19. 
The control selected for a particular case was the one closest to 
the case in terms of distance. Analyses were then performed on the 
two matched groups (BVS vs. EES), stratified by pairs to account 
for propensity score matching. For the study, individual data were 
pooled on a patient-level basis. Categorical variables are reported 
as counts and percentages, continuous variables as mean±standard 
deviation. The Student’s t-test and the chi-square test (or Fisher’s 
exact test) were used for comparison of means and percentages. 
The cumulative incidence of adverse events was estimated accord-
ing to the Kaplan-Meier method. Patients lost to follow-up were 
considered at risk until the date of last contact, at which point they 
were censored. Kaplan-Meier estimates were compared by means 
of the log-rank test. For the endpoint MACE, a landmark survival 
analysis was performed with the landmark time point at 30 days. 
All statistical tests were two-sided and a p-value of <0.05 was 
considered statistically significant.
Results
A total of 1,306 patients presenting with acute ST-segment eleva-
tion myocardial infarction were evaluated for the present analysis 
(161 patients implanted with BVS and 1,145 patients implanted 
with EES with at least two-year follow-up available). After match-
ing, 302 patients treated with either BVS or EES (151 patients 
treated with BVS matched with 151 patients treated with EES) 
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Midterm outcomes of BVS in STEMI
were analysed. Six patients (3.9%) in the BVS group declined to 
participate in follow-up.
Baseline clinical characteristics were balanced between the 
groups, as shown in Table 1.
A total of 403 devices (193 BVS) were deployed, and aspi-
ration thrombectomy was performed equally in the two groups 
(BVS 76.7% vs. 76.8% EES, p=1.000). Predilatation was per-
formed more frequently in the BVS group (54.1% vs. 28.4%, 
p<0.001) with a higher balloon/artery ratio (1.02±0.24 vs. 
0.88±0.21, p=0.002). Post-dilatation was also performed more 
frequently in the BVS group (39.7% vs. 21.8%, p<0.001, respec-
tively), but with a balloon/scaffold-stent ratio higher in the EES 
group (1.07±0.09 vs. 1.12±0.12, p=0.031). The BVS group rate 
of post-dilatation increased over time during the inclusion: in 
the first 75 patients the rate of post-dilatation was 25.3%, while 
in the remaining 76 patients it was 53.9%. Device success was 
similar between groups (98.7% vs. 99.3%, p=1.000) (Table 2).
Baseline culprit vessels, vessel dimensions, percentage of ste-
nosis, TIMI flow and thrombotic burden were similar between 
patients treated with BVS and those treated with EES (Table 3).
At the end of the procedure, there were no cases of TIMI flow 
0, and final TIMI 3 flow was achieved in 87.4% and 86.1% of the 
BVS and EES groups, respectively (p=0.296), with similar mini-
mal lumen diameter and percentage stenosis.
SIX-MONTH CLINICAL OUTCOMES
All-cause death was observed in 2.1% vs. 2.0% of the cases in the 
BVS and EES groups respectively, p=0.97; the rate of any myo-
cardial infarction was 5.5% in the BVS group and 1.3% in the 
EES group, p=0.05. The target lesion revascularisation rate was 
3.5% and 1.3%, respectively, p=0.23. Acute scaffold thrombosis 
occurred in 2.1% of BVS implanted patients and 0.7% of EES 
Table 1. Baseline clinical characteristics.
BVS (N=151) EES (N=151) p-value
Age, years 56.31±10.22 54.90±11.52 0.263
Male 109/151 (72.2) 113/151 (74.8) 0.696
Active smoker 71/151 (41.0) 89/151 (58.9) 0.050
Diabetes mellitus 17/151 (11.3) 15/151 (9.9) 0.852
Dyslipidaemia 43/151 (28.4) 41/151 (27.1) 0.226
Hypertension 60/151 (39.7) 56/151 (37.1) 0.723
Family history 51/151 (33.8) 52/151 (34.4) 1.000
Target vessel 0.520
LAD 64/151 (42.4) 62/151 (41.1)
LCX 32/151 (21.2) 40/151 (26.5)
RCA 51/151 (33.8) 46/151 (30.5)
Diagonal 2/151 (1.3) 3/151 (2.0)
Ramus intermedius 2/151 (1.3) 0
Left main 0 0
SVG 0 0
Data are expressed as count and proportion (%) or mean±standard 
deviation.
Table 2. Procedural characteristics.
BVS (N=151) EES (N=151) p-value
Aspiration thrombectomy 115/151 (76.7) 116/151 (76.8) 1.000
Predilatation performed 80/151 (54.1) 42/151 (28.4) <0.001
Predilatation balloon/artery ratio 1.02±0.24 0.88±0.21 0.002
Maximal diameter balloon 
predilatation, mm 2.54±0.47 2.40±0.48 0.111
Supportive wire used 18/151 (12.2) 3/151 (2.0) <0.001
Device failure 2/151 (1.5) 1/151 (0.7) 1.000
Device success 149/151 (98.7) 150/151 (99.3) 1.000
Procedure success 148/151 (98.0) 150/151 (99.3) 0.622
Mean scaffold diameter, mm 3.21±0.33 3.20±0.46 0.827
Mean total nominal scaffold length, mm 26.32±13.27 27.76±14.81 0.378
Number of scaffolds deployed per 
treated vessel 1.28±0.61 1.39±0.73 0.148
0 2 (1.3) 0 0.398
1 115 (76.2) 108 (71.5)
2 25 (16.6) 32 (21.2)
3 8 (5.3) 7 (4.6)
4 1 (0.7) 3 (2.0)
5 0 1 (0.7)
Procedures with overlapping scaffolds 31/151 (20.7) 39/151 (25.8) 0.340
Post-dilatation performed 60/151 (39.7) 33/151 (21.8) <0.001
Post-dilatation balloon/scaffold or stent 
ratio 1.07±0.09 1.12±0.12 0.031
Maximal post-dilatation balloon 
diameter, mm 3.45±0.41 3.54±0.59 0.435
Complications occurring anytime during the procedure
Any dissection 10/151 (6.7) 8/151 (5.3) 0.809
Thrombosis 0 0
Perforation 1/151 (0.7) 0
Data are expressed as count and proportion (%) or mean±standard deviation.
implanted patients, p=0.29. In both groups the subacute ST rate 
was 0.7%, p=0.99. All three acute scaffold thromboses occurred in 
patients without post-dilatation performed at the index procedure. 
The overall MACE rate was 7.6% vs. 2.7%, p=0.06. A landmark 
analysis showed that the 30-day MACE rate in BVS patients with-
out post-dilatation was 6.8%, while in patients with post-dilatation 
it was 3.6%.
12-MONTH CLINICAL OUTCOMES
From six to 12-month follow-up, one non-cardiac death, one tar-
get lesion revascularisation and one non-target vessel revasculari-
sation occurred in the group treated with a bioresorbable vascular 
scaffold.
18-MONTH CLINICAL OUTCOMES
From 12 to 18 months, two cases of very late scaffold thrombo-
sis were observed in the BVS group, at 416 and 449 days after 
implantation (Figure 2). In both cases the dual antiplatelet ther-
apy was interrupted (per protocol) at the moment of the event. 
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Discussion
The feasibility of BVS implantation in patients presenting with 
acute myocardial infarction has recently been reported with 
preliminary information on short-term clinical outcomes11-13. 
However, data comparing the midterm performance of the biore-
sorbable technology with the current generation of metal DES in 
this specific subset are limited. The present study represents an 
initial experience evaluating the use of the second-generation BVS 
for the treatment of patients presenting with STEMI in compari-
son with everolimus-eluting metal stents in terms of acute angio-
graphic results and 18-month clinical outcomes.
The majority of the treated patients presented with TIMI flow 0 
or 1, and more than 60% of the lesions had a large thrombus bur-
den (four or five) in the culprit vessel, in line with recent large 
STEMI trials with minimal exclusion criteria20,21.
Procedural and angiographic data showed an overall compa-
rable device success rate between the two groups, with a similar 
intraprocedural complication rate. At the end of the procedure, 
the restoration of TIMI 3 flow was achieved in a large number of 
patients and similarly in both groups, with comparable acute lumen 
gain, percentage diameter stenosis and minimal lumen diameter.
On the other hand, at 18-month follow-up, MACE rate was 
higher in the BVS group. Importantly, most events occurred in the 
very early phase after implantation. In particular, three scaffold 
thromboses occurred within 24 hours following the index proce-
dure and in none of them was a post-dilatation performed.
Notably, this registry enrolled patients at a time when post-dila-
tion was not regarded to be key for optimal implantation and clini-
cal results, especially in the acute subset. Studies reporting pooled 
BVS data from different European registries performed in the 
same era showed similar rates of scaffold thrombosis at 30 days13.
A consortium of experienced European experts has recently 
emphasised the importance of high-pressure post-dilation with 
BVS22 and, in our study, the uptake of post-dilatation with BVS 
doubled over the course of this registry. Furthermore, an optimised 
implantation strategy including systematic post-dilatation has been 
shown to be associated with a reduction in thrombotic events23.
Table 3. Angiographic characteristics.
BVS (N=151) EES (N=151) p-value
Pre-procedure
TIMI flow 0.213
0 80/151 (53.0) 85/151 (56.3)
1 16/151 (10.6) 12/151 (7.9)
2 31/151 (20.5) 40/151 (26.5)
3 24/151 (15.9) 14/151 (9.3)
Thrombus burden 0.551
1 24/148 (16.2) 20/150 (13.3)
2 21/148 (14.2) 16/150 (10.7)
3 12/148 (8.1) 9/150 (6.0)
4 12/148 (8.1) 18/150 (12.0)
5 79/148 (53.4) 87/150 (58.0)
Total thrombotic occlusion
RVD (mm) 2.76±0.72 2.71±0.47 0.608
Non-total thrombotic occlusion
RVD (mm) 2.60±0.52 2.72±0.54 0.179
MLD (mm) 0.82±0.46 0.91±0.66 0.335
Diameter stenosis (%) 68.07±15.08 66.27±21.57 0.571
Post-procedure
TIMI flow 0.296
0 0 0
1 2/151 (1.3) 0/151
2 17/151 (11.3) 21/151 (13.9)
3 132/151 (87.4) 130/151 (86.1)
RVD (mm) 2.63±0.54 2.98±1.76 0.023
MLD (mm) 2.11±0.50 2.22±0.54 0.067
Diameter stenosis (%) 20.64±11.02 22.28±9.92 0.181
Acute lumen gain 1.98±0.67 2.06±0.73 0.398
Data are expressed as count and percentages or mean±standard deviation.
In both cases the review of intravascular imaging showed scaf-
fold malapposition. In the EES group, two additional non-TVR 
were reported, one of them associated with a myocardial infarc-
tion (Table 4).
Figure 2. Cases of very late scaffold thrombosis. Both cases were performed with satisfactory final angiographic results. Case 1 (panels A-E): 
A) baseline; B) final result of the index procedure; C) thrombosis; D) final result of the event treatment. Post-dilatation was performed during 
the index intervention, but at the end of the procedure intravascular imaging (E) highlighted the remaining malapposition (*). Case 2 (panels 
F-J): G) baseline; H) final result of the index procedure; I) thrombosis; J) final result of the event treatment. At the time of the event, 
intravascular imaging (F) showed persistent malapposition (**).
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In the randomised Absorb-TROFI II trial, evaluating short-term 
imaging results in either BVS or EES in acute myocardial infarc-
tion, the rate of subacute scaffold thrombosis was 1.1% at six-month 
follow-up. In this study, the implantation technique was slightly dif-
ferent from ours, including mandatory thrombus aspiration and post-
dilation performed in a slightly higher number of cases24.
Our study further highlighted the importance of post-dilatation 
with BVS because patients without post-dilatation had a higher 
MACE rate in the first month, and both cases of very late scaf-
fold thrombosis were associated with persistent malapposition. 
We therefore hypothesise that an optimal BVS implantation tech-
nique, encompassing adequate pre- and post-dilatation is essen-
tial for improving clinical outcomes also in the acute clinical 
setting.
The minimalist PCI approach in STEMI, focussing on resto-
ration of TIMI 3 flow in the culprit vessel with a minimum of 
manoeuvres to minimise the risk of distal embolisation, may not 
be valid with BVS. The observations reported in the present study 
could support a more frequent use of post-dilatation to optimise 
scaffold expansion, even in acute patients. Large randomised trials 
currently in preparation may add to our understanding of the real 
performance of bioresorbable technologies in the acute setting.
Limitations
The number of subjects evaluated in the present study is limited, 
and data on clinical outcomes should be considered descriptive 
and hypothesis-generating. The two study groups were not ran-
domised. Despite the use of propensity matching, unadjusted 
confounders might remain, possibly having an impact on results. 
A larger patient population and longer follow-up would be needed 
for adequate comparison of this novel technology with current-
generation metal DES.
Conclusion
STEMI patients treated with PCI and BVS in the early experi-
ence had similar acute angiographic results as compared to EES. 
Clinical midterm follow-up data showed a higher clinical events 
rate compared with metal stents. The majority of clinical events 
occurred in the early phase after implantation and mainly in cases 
without post-dilatation. Optimisation of the implantation tech-
nique is relevant in acute patients for achieving optimal short and 
mid-term clinical outcomes.
Guest Editor
This paper was guest edited by Tommaso Gori, MD, PhD; Zentrum 
für Kardiologie, Universitätsmedizin Mainz, University Medical 
Center, Mainz and DZHK Rhein-Main, Germany.
Impact on daily practice
Implantation of bioresorbable vascular scaffolds requires 
a meticulous lesion preparation and an adequate optimisa-
tion of scaffold expansion with a frequent use of high pres-
sure post-dilatation. Our results after early experience in 
patients presenting with acute myocardial infarction, showed 
a slightly higher rate of events in patients implanted with 
bioresorbable vascular scaffolds. Procedural factors might 
have had a role in these findings and an optimal implanta-
tion technique, including high pressure post-dilatation should 
also be considered in the acute setting when using bioresorb-
able scaffolds.
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Table 4. Clinical outcomes.
6-month follow-up 12-month follow-up 18-month follow-up
BVS (n=145) EES (n=151) p-value BVS (n=145) EES (n=151) p-value BVS (n=145) EES (n=151) p-value
All-cause death 3 (2.1) 3 (2.0) 0.97 4 (2.8) 3 (2.0) 0.68 4 (2.8) 4 (3.0) 0.99
Cardiac death 3 (2.1) 2 (1.3) 0.63 3 (2.1) 2 (1.3) 0.63 3 (2.1) 2 (1.3) 0.63
MACE 11 (7.6) 4 (2.7) 0.06 12 (8.1) 4 (2.7) 0.03 14 (9.8) 5 (3.6) 0.03
MI 8 (5.5) 2 (1.3) 0.05 8 (5.5) 2 (1.3) 0.05 9 (6.3) 3 (2.3) 0.07
TLR 5 (3.5) 2 (1.3) 0.23 6 (4.2) 2 (1.3) 0.14 8 (5.7) 2 (1.3) 0.05
Non-TVR 3 (2.1) 3 (2.0) 0.97 4 (2.8) 3 (2.0) 0.67 5 (3.6) 5 (4.0) 0.95
Definite ST 4 (2.8) 2 (1.3) 0.38 4 (2.8) 2 (1.3) 0.38 6 (4.3) 2 (1.3) 0.15
Acute 3 (2.1) 1 (0.7) 0.29 3 (2.1) 1 (0.7) 0.29 3 (2.1) 1 (0.7) 0.29
Subacute 1 (0.7) 1 (0.7) 0.99 1 (0.7) 1 (0.7) 0.99 1 (0.7) 1 (0.7) 0.99
Late – – – – – – 0 (0.0) 0 (0.0) –
Very late – – – – – – 2 (1.5) 0 (0.0) 0.18
Data are expressed as count and percentages
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